Navigation Links
BioMS Medical updates University of Alberta equity position
Date:4/30/2010

Toronto Stock Exchange Symbol: MS

EDMONTON, April 30 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), today announced that the University of Alberta, a major shareholder of the Company, has sold 12,915,365 BioMS Medical shares.

Certain employees, officers and directors of BioMS Medical acquired 7,245,000 of the shares sold by the University of Alberta.

"We are very pleased that many of our senior management and Board members saw this as an opportunity to purchase these shares, recognizing the long-term prospects for the Company," said Kevin Giese, President and CEO of BioMS Medical. "We also thank the University of Alberta for their support over the past 10 years and continued involvement as a shareholder."

University of Alberta Vice President (Finance) Phyllis Clark added: "We have enjoyed a long and collaborative relationship with BioMS which we look forward to continuing in the future. The proceeds from the sale will be used to support the endowment fund and the teaching and research mission of the university."

About BioMS Medical Corp.

BioMS Medical is a biotechnology company engaged in the investment, development and commercialization of pharmaceutical technologies. For further information please visit our website at http://www.biomsmedical.com

This press release may
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical Announces 2009 Year End Results
2. BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
3. Spectral diagnostics Raises $14 million and enters into strategic collaboration with BioMS Medical to commercialize treatment for sepsis
4. BioMS Medical provides corporate update
5. BioMS Medical Announces Third Quarter 2009 Results
6. BioMS Medical announces second quarter 2009 results
7. BioMS Medical to present at the 2009 Symposium for the Canadian Society for Pharmaceutical Sciences
8. BioMS Medical to participate in panel session at Bio International Convention 2009
9. BioMS Medical Announces First quarter 2009 results
10. BioMS Medical to present at Alberta Economic Forum in Geneva
11. BioMS Medical to present at BioFinance 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Muncie, IN (PRWEB) July 25, 2014 ... Administration (FAA) has granted a 60-day extension for the ... of the Special Rule for Model Aircraft established by ... Act of 2012. The 60-day extension establishes the new ... the United States Department of Transportation/FAA notice published in ...
(Date:7/24/2014)... July 24, 2014 Gain recognition ... Supply Chain of the biotech industry. Nominations are ... Awards, brought to you by the Bio ... of supply chain management professionals for the past ... stakeholders of the Biotech industry – Manufacturers, Service ...
(Date:7/24/2014)... forces worldwide rely on sophisticated equipment, trained personnel, ... public areas against terrorist attacks. A revolutionary new ... to make their job much easier. , The ... of Tel Aviv University ,s School of Chemistry ... by the Herzliya company Tracense, picks up the ...
(Date:7/24/2014)... natural and synthetic processes prefer to settle into ... energyit is within the realm of non-equilibrium conditions ... changes in energy and phases, such as temperature ... allow humans to regulate their body temperature, airplanes ... seismic activity. , But even though these ...
Breaking Biology Technology:FAA Grants Comment Extension at the Request of AMA 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Nano-sized chip 'sniffs out' explosives far better than trained dogs 2New approach to form non-equilibrium structures 2
... 2 According to the National Institute of Health, 40 percent ... stage of diabetic retinopathy. Diabetic retinopathy, damage to the retina ... in people with diabetes and is one of the most feared ... patients who,ve had diabetes for 10 years or more will experience ...
... , ... that a new market research report is available in ... Trends , http://www.reportlinker.com/p0164494/Chromium---Global-Market-Trends.html , Worldwide ... while growth in aerospace and industrial gas turbine markets ...
... PLYMOUTH, Mass., Dec. 1 Harvest Technologies Corp. ( ... 60-patient clinical trial conducted at Sri Ramachandra Medical Center ... treat patients with non-reconstructable Critical Limb Ischemia (CLI). Sri ... based in Chennai, India and one of the largest ...
Cached Biology Technology:Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4Reportlinker Adds Chromium - Global Market Trends 2Reportlinker Adds Chromium - Global Market Trends 3Reportlinker Adds Chromium - Global Market Trends 4Reportlinker Adds Chromium - Global Market Trends 5Reportlinker Adds Chromium - Global Market Trends 6Reportlinker Adds Chromium - Global Market Trends 7Reportlinker Adds Chromium - Global Market Trends 8Reportlinker Adds Chromium - Global Market Trends 9Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 2Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 3
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
... Institutes of Health announced today that it will fund ... -- chemical modifications to genes that result from diet, ... to specific human diseases and biological processes. ... as part of the NIH Roadmap for Medical Research,s ...
... University is being honored for one of its programs ... institute,s intern program has received the roundtable group,s Most ... award, as the best pollution prevention project/program. The honor ... The award is presented based on a program,s ...
... LA JOLLA, Calif., September 15, 2009 -- Researchers ... have discovered that reactive oxygen species, such as ... in forming invadopodia, cellular protrusions implicated in cancer ... professor and director of the Tumor Microenvironment Program ...
Cached Biology News:NIH funds grantees focusing on epigenomics of human health and disease 2NIH funds grantees focusing on epigenomics of human health and disease 3NIH funds grantees focusing on epigenomics of human health and disease 4K-State Pollution Prevention Institute's intern program named best 2Reactive oxygen's role in metastasis 2
Mouse monoclonal [3576] to Yellow Fever Virus ( Abpromise for all tested applications). Antigen: Tissue / cell preparation...
... 2 Detection System combines the indirect ... principle and Signets unique formulation of ... and reliablility. Signet reagents will achieve ... and automated protocols. ,Signets USA ...
6X Loading Buffer is intended for gel electrophoresis of DNA fragments or PCR products....
Ideally suited for resolving DNA and RNA 10-1000 bases especially PCR products ranging from 100-1000 bp. Gelling temp. (4%) 27C Melting temperature 65C. EEO: 0.10 Rnase/Dnase: none detected...
Biology Products: